γ-secretase modulator. Reduces Aβ42 levels in vitro (EC50 = 390 nM) and in vivo. Orally bioavailable.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 499.54. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2 mL||10.01 mL||20.02 mL|
|5 mM||0.4 mL||2 mL||4 mL|
|10 mM||0.2 mL||1 mL||2 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the biological activity of the product.
Peng et al (2011) Discovery of BIIB042, a potent, selective, and orally bioavailable γ-secretase modulator. ACS Med.Chem.Lett. 2 786 PMID: 24900267
If you know of a relevant reference for TC-E 5006, please let us know.
View Related Products by Product Action
Keywords: TC-E 5006, TC-E 5006 supplier, TC-E5006, biib042, γ-secretase, g-secretase, gamma-secretase, modulators, Aβ42, AB42, Abeta42, amyloid, Gamma-Secretase, 4898, Tocris Bioscience
Citations for TC-E 5006
Citations are publications that use Tocris products.
Currently there are no citations for TC-E 5006. Do you know of a great paper that uses TC-E 5006 from Tocris? Please let us know.
Reviews for TC-E 5006
There are currently no reviews for this product. Be the first to review TC-E 5006 and earn rewards!
Have you used TC-E 5006?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.